Zai Lab Limited (NASDAQ:ZLAB) Shares Sold by Segantii Capital Management Ltd

Segantii Capital Management Ltd lowered its stake in Zai Lab Limited (NASDAQ:ZLAB) by 5.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,687,569 shares of the company’s stock after selling 101,430 shares during the period. Zai Lab accounts for 2.5% of Segantii Capital Management Ltd’s holdings, making the stock its 12th biggest position. Segantii Capital Management Ltd’s holdings in Zai Lab were worth $46,465,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Hsbc Holdings PLC lifted its position in Zai Lab by 251.1% during the third quarter. Hsbc Holdings PLC now owns 327,781 shares of the company’s stock valued at $7,968,000 after purchasing an additional 234,431 shares during the period. UBS Group AG boosted its stake in shares of Zai Lab by 312.4% in the third quarter. UBS Group AG now owns 288,981 shares of the company’s stock worth $7,025,000 after buying an additional 218,907 shares during the last quarter. XY Capital Ltd acquired a new stake in Zai Lab during the third quarter worth about $3,397,000. TD Asset Management Inc boosted its position in Zai Lab by 114.6% in the 3rd quarter. TD Asset Management Inc now owns 216,970 shares of the company’s stock worth $5,275,000 after purchasing an additional 115,885 shares in the last quarter. Finally, Bamco Inc. NY grew its stake in shares of Zai Lab by 4.5% during the 3rd quarter. Bamco Inc. NY now owns 1,579,349 shares of the company’s stock worth $38,394,000 after purchasing an additional 67,288 shares during the period. 41.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a report on Friday, January 12th. Citigroup dropped their target price on Zai Lab from $123.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $64.22.

Insiders Place Their Bets

In related news, insider Rafael Amado sold 2,544 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $18.86, for a total value of $47,979.84. Following the completion of the sale, the insider now owns 20,093 shares of the company’s stock, valued at $378,953.98. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Joshua L. Smiley sold 1,988 shares of the company’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total value of $31,151.96. Following the transaction, the insider now owns 28,684 shares of the company’s stock, valued at approximately $449,478.28. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Rafael Amado sold 2,544 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $18.86, for a total value of $47,979.84. Following the sale, the insider now directly owns 20,093 shares of the company’s stock, valued at $378,953.98. The disclosure for this sale can be found here. Insiders have sold 12,568 shares of company stock valued at $208,508 in the last ninety days. 5.23% of the stock is currently owned by corporate insiders.

Zai Lab Stock Up 26.8 %

Shares of NASDAQ ZLAB traded up $4.44 during midday trading on Thursday, hitting $21.01. The stock had a trading volume of 3,671,088 shares, compared to its average volume of 651,174. Zai Lab Limited has a 1 year low of $13.48 and a 1 year high of $39.50. The company has a market capitalization of $2.08 billion, a PE ratio of -5.97 and a beta of 1.11. The stock has a 50 day simple moving average of $16.78 and a 200-day simple moving average of $22.12.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.38. The company had revenue of $87.15 million for the quarter, compared to analysts’ expectations of $77.07 million. Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. During the same quarter in the previous year, the company posted ($0.51) EPS. As a group, analysts expect that Zai Lab Limited will post -3.27 earnings per share for the current fiscal year.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.